Chapter 2 42 Figure 2. PD-1T TILs can effectively discriminate patients with long-term benefit from patients with progressive disease. (A) ROC curve for predictive value of PD-1T TILs for DC 12m in the training set (n=43) (AUC 0.89; 95% CI: 0.73-1.00) and (B) in the validation set (n=77) (AUC 0.78; 95% CI: 0.68-0.88). (C) Percentage of patients with PD-1T high (≥90 per mm2) (n=16) and PD-1T low (<90 per mm2) (n=27) pretreatment samples in the training set showing DC 12m or PD. (D) Same plot as in C for PD-1T high (n=35) and PD-1T low (n=42) pretreatment samples in the validation set (n=77). (E) Progression-free survival (PFS) of patients with PD-1T high versus PD-1T low pretreatment samples (median 5.7 versus 2.2 months, HR 0.39; 95% CI: 0.240.63, **** P<0.0001) in the validation set (n=77). (F) Overall survival (OS) (median 10.7 versus 6.5 month, HR 0.46; 95% CI: 0.28-0.76, ** P<0.01). Tick marks represent data censored at the last time the patient was known to be alive and without disease progression or death. P-value was determined by log-rank test.
RkJQdWJsaXNoZXIy MTk4NDMw